Clinical Data Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer BioSpaceA triplet regimen comprising Merck's Welireg and PD-1 blockbuster Keytruda and Eisai's Lenvima flopped in a Phase 3 renal cell carcinoma trial.Clinical DataOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) BioSpace A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial. Clinical DataOncologyRead full story Post navigation Previous: Novo Nordisk preps filings for sickle cell drug etavopivatNext: Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026